Phase Ⅰ/Ⅱa Trial Evaluating Intravenous hUC-MSCs Injection for Safety, Tolerability and Efficacy in Patients With POI
Key facts
- Who runs it
- Shenzhen Wingor Biotechnology Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 59 people, planned
- Started
- 3 Aug 2026
- Expected to end
- 2 Aug 2029
- Type of study
- Interventional, 6 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- hUC-MSCs Injection (Phase I)
- hUC-MSCs Injection (Phase IIa)
- Placebo
- Record updated
- 20 August 2026
Who can take part
- Age
- 18 years to 40 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Aged 18 to 40 years at the time of signing the informed consent form (exclusive of the boundary values)
- Meet the diagnostic criteria specified in the Expert Consensus on Clinical Diagnosis and Treatment of Premature Ovarian Insufficiency (2023 Edition): oligomenorrhea (menstrual cycle longer than 35 days) or amenorrhea for more than 4 months, with basal serum follicle-stimulating hormone (FSH) > 25 U/L (tested on Days 2-4 of the menstrual cycle or during amenorrhea, at least twice with an interval of ≥4 weeks)
- Satisfy one of the following two criteria:; Total number of antral follicles (AFC) with a diameter of 2-10 mm in bilateral ovaries < 5; Serum anti-Müllerian hormone (AMH) ≤ 7.85 pmol/L (equivalent to 1.1 ng/mL)
- Have received standardized hormone replacement therapy (HRT) at a stable dose for ≥3 months prior to drug administration with stable hormone levels, and maintain stable HRT per medical advice throughout the trial (within 24 weeks after enrollment)
- Have no fertility requirements
- Agree to use effective contraceptive measures throughout the trial period (such as complete abstinence, condoms, cervical caps plus spermicides, intrauterine devices, etc.)
- Negative serum β-hCG test result during the screening period (to rule out pregnancy)
- Fully understand the trial information and sign the informed consent form
Who cannot take part
- Subjects receiving or planning to use the following medications during the trial: oral or systemic corticosteroids, danazol, anticoagulants, Chinese herbal medicines or botanical supplements that may affect hormone levels or ovarian function
- Participation in another clinical trial within the past 3 months, or receipt of other cell therapies (excluding blood transfusion)
- Subjects with thyroid disorders (hypothyroidism/hyperthyroidism or thyroid malignant tumors) or resistant ovary syndrome (ROS)
- Subjects with abnormal female karyotypes (e.g., Turner syndrome, Fragile X syndrome)
- Positive serology tests (HBV antibody, HCV antibody, HIV antibody, syphilis). Exceptions: HBV carriers, patients with stable HBV after drug treatment (HBV DNA titer ≤500 IU/mL or copies <1000 copies/mL), and patients with cured HCV (negative HCV RNA test) may be enrolled if deemed eligible by the investigator
- History of malignant tumors
- Uncontrolled diabetes, hypertension (>150/100 mmHg), heart disease, etc
- Any other conditions judged by the investigator to render the subject unsuitable for participation in this study
- History of hypersensitivity to human serum albumin
- Subjects with contraindications or cautions for estrogen use, including known or suspected breast cancer, endometrial cancer, other known or suspected sex hormone-dependent malignancies, active venous or arterial thromboembolic diseases within the last 6 months, undiagnosed abnormal genital bleeding, severe hepatic or renal insufficiency [serum aspartate aminotransferase (AST) >3×ULN, serum alanine aminotransferase (ALT) >3×ULN, estimated glomerular filtration rate (eGFR) <60 mL/min], etc
- Subjects with primary amenorrhea
- Pregnant or breastfeeding subjects
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A Phase I/IIa clinical study evaluating the safety, tolerability and efficacy of intravenously administered human umbilical cord mesenchymal stem cell (hUC-MSCs) injection in patients with premature ovarian insufficiency (POI).
Read full original descriptionShow less
The primary objective of the Phase I dose-escalation stage is to assess the safety and tolerability of intravenous infusion of hUC-MSCs injection for the treatment of POI, and to determine the recommended phase II dose (RP2D) for the Phase IIa clinical trial.
The primary objective of the Phase IIa dose-expansion stage is to evaluate the efficacy of intravenous infusion of hUC-MSCs injection in POI treatment, and to generate data to support pivotal/confirmatory clinical trials.
The 6 groups in the trial
- Phase I, Dose Cohort 1Treatment being tested
Human Umbilical Cord Mesenchymal Stem Cells Injection
Treatment: hUC-MSCs Injection (Phase I)
- Phase I, Dose Cohort 2Treatment being tested
Human Umbilical Cord Mesenchymal Stem Cells Injection
Treatment: hUC-MSCs Injection (Phase I)
- Phase I, Dose Cohort 3Treatment being tested
Human Umbilical Cord Mesenchymal Stem Cells Injection
Treatment: hUC-MSCs Injection (Phase I)
- Phase IIa, Medium-Dose CohortTreatment being tested
Human Umbilical Cord Mesenchymal Stem Cells Injection
Treatment: hUC-MSCs Injection (Phase IIa)
- Phase IIa, High-Dose CohortTreatment being tested
Human Umbilical Cord Mesenchymal Stem Cells Injection
Treatment: hUC-MSCs Injection (Phase IIa)
- Phase IIa, Placebo CohortPlacebo, for comparison
Multiple Electrolytes Injection
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase Ⅰ/Ⅱa Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Injection of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in Patients With Premature Ovarian Insufficiency (POI)
- Criteria questions
- Built from NCT07775391, who can take part
- Record updated
- 20 August 2026